Navigation Links
Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class
Date:7/13/2009

SAN DIEGO, July 13 /PRNewswire/ -- Research published in the June 26, 2009 edition of Proceedings of National Academy of Sciences provides further evidence for novel roles of tRNA synthetases in disease, validating the therapeutic potential for aTyr Pharma's new class of naturally occurring protein agents. The aminoacyl tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, but human synthetases have naturally occurring resected variants with potent cell signaling activities that are vital to normal functioning of humans. aTyr Pharma's proprietary product generating engine consists of these resected proteins (resectins) of human aminoacyl tRNA synthetases with cell signaling activities distinct from the protein synthesis activities. In this recently published study, a model of a human neuropathy was created in the fruit fly (Drosophila) by introducing mutations in the tyrosyl-tRNA synthetase which correspond to disease associated mutations in humans. These dominant mutations do not cause a loss in the protein synthesis activity, indicating that the neuropathy arises from distinct activities of this tRNA synthetase. This work provides further proof of noncanonical roles for tRNA synthetases in human disease.

The large team of scientists on the study included Professors Paul Schimmel and Xiang-Lei Yang, scientific co-founders of aTyr Pharma, and Leslie Nangle, Director of Research at aTyr Pharma, and was led by Albena Jordanova of the University of Antwerp. Other scientists contributing to this paper are from the University of Antwerp, Universiteit Leuven, and Florida Atlantic University. Professor Paul Schimmel of The Scripps Research Institute describes the significance of the work. "Charcot-Marie-Tooth (CMT) is one of the most common inherited neurological disorders, with typical symptoms usually emerging in early adulthood,
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
2. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
3. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
6. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. Researchers Train the Immune System to Deliver Virus That Destroys Cancer in Lab Models
11. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 28, 2015 Baebies, Inc. today announced ... $13 million. The oversubscribed round of financing included key ... Duke endowment), Cunning Capital, Triad, LLC, the Duke Angel ... Center. Many of Advanced Liquid Logic,s (ALL) former investors ... invested. "Rex is pleased to support ...
(Date:7/28/2015)... ATLANTA, July 28, 2015  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... months of 2015.  Pat Mackin, Chairman, ... we continued to execute on our growth strategy with ... In June, we announced plans to transition to a ...
(Date:7/28/2015)... Fla. , July 28, 2015 ... Spectralink, the global leader in purpose-built wireless communications, ... (Bay Area Regional), a 104-bed acute-care facility in ... to implement the Voalte One™ solution on Spectralink ... "Since Spectralink named Voalte a member of ...
Breaking Medicine Technology:Baebies, Inc. Raises $13 Million in Oversubscribed Round of Financing 2CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3
(Date:7/29/2015)... Hendersonville, TN (PRWEB) , ... July 29, 2015 ... ... the Value-Added Solutions Group, which Breckheimer oversees. In her role, Powers is responsible ... , Upon making the announcement, Breckheimer commented, “Gina’s track record as an effective ...
(Date:7/28/2015)... ... July 29, 2015 , ... Meet a Millionaire, the ... has evolved into a world class millionaires club, according to the site’s founders. ... and attractive people seeking real, meaningful and mutually beneficial relationships and provide a ...
(Date:7/28/2015)... ... July 29, 2015 , ... The ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting more than 700,000 members and ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Every July, since ... with the disease only experience through movies and television. They go to summer camp. ... the right side of the heart as it pushes hard to get blood through ...
(Date:7/28/2015)... ... July 28, 2015 , ... Jordan Valley Medical Center and ... Guidelines®-Stroke Gold Plus Award for implementing specific quality improvement measures outline by the ... Get With The Guidelines-Stroke program recognizes hospitals that demonstrate at least 85 percent ...
Breaking Medicine News(10 mins):Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3Health News:Meet a Millionaire Announces It’s Not a Sugar Daddy Site, It’s a True Millionaires Club 2Health News:National Association of Professional Women Inducts Susan Bentley, Owner of Women's Wellness Options, Into its VIP Woman of the Year Circle 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 2Health News:Special Summer Camp Gives Pulmonary Hypertension Patients Experiences Typically Out of Reach for Kids with their Condition 3Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3
... Preliminary studies had suggested possible problems with Prilosec and ... A U.S. government review of the popular heartburn ... heart risks, health officials said Monday. , The announcement ... heart risks emerged from two preliminary studies. But detailed ...
... JPMorgan,s Annual,Healthcare Conference, which celebrates its 26th ... the Westin St. Francis Hotel in San Francisco., ... feature,presentations from approximately 300 companies, both public and ... event will include,panel discussions with leading private equity ...
... MGCD0103 Determined as 90 mg, * 53% of Patients Treated ... Experienced a 66% Reduction in the Risk of Death ... Compared to Non-responders, ATLANTA, ... MYG) today announced maturing data,from the Phase 1/2 study investigating the combined ...
... in Three Gorgeous Tints!, SAN JOSE, Calif., Dec. ... ) today announced the addition of two,new colors to ... SPF 30 with PhytoMelanin. The sunscreen widely recommended by,physicians ... skin tone., Jan Marini,s original tinted shade, a ...
... Dec. 10 For the past 30 years,the ... forum of interaction and,exchange among scientists and clinicians ... is an educational milieu providing an ideal format ... and late breaking data, as,well as other pertinent ...
... with a milder chemotherapy regimen before they receive a ... long-term complete remission for 45 of 47 patients in ... M. D. Anderson Cancer Center report at the 49th ... , The two patients who had relapsed after the ...
Cached Medicine News:Health News:FDA Confirms No Heart Risk From Heartburn Drugs 2Health News:FDA Confirms No Heart Risk From Heartburn Drugs 3Health News:JPMorgan's 26th Annual Healthcare Conference Media Advisory 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:Jan Marini Skin Research Adds Two New Sheer Colors to Antioxidant Daily Face Protectant SPF 30 With PhytoMelanin(TM) 2Health News:San Antonio Breast Cancer Symposium December 13th to 16th 2007 2Health News:Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma 2
Angled 45 degrees. Open 13 mm blades. Screw-controlled locking mechanism. Dull finish....
Open blade design with aspiration capabilities for removing fluids from the operative site....
Solid 15 mm blades with 8 mm narrowed portion. Screw-controlled locking mechanism with stabilizing disk. Dull finish....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Medicine Products: